153 related articles for article (PubMed ID: 36001859)
1. Bayesian Sample Size Planning Tool for Phase I Dose-Finding Trials.
Lin X; Lyu J; Yuan S; Bi D; Wang SJ; Ji Y
JCO Precis Oncol; 2022 Aug; 6():e2200046. PubMed ID: 36001859
[TBL] [Abstract][Full Text] [Related]
2. Uniformly most powerful Bayesian interval design for phase I dose-finding trials.
Lin R; Yin G
Pharm Stat; 2018 Nov; 17(6):710-724. PubMed ID: 30066466
[TBL] [Abstract][Full Text] [Related]
3. Sample size re-estimation in Phase 2 dose-finding: Conditional power versus Bayesian predictive power.
Liu Q; Hu G; Ye B; Wang S; Wu Y
Pharm Stat; 2023 Mar; 22(2):349-364. PubMed ID: 36418025
[TBL] [Abstract][Full Text] [Related]
4. A curve-free Bayesian decision-theoretic design for two-agent Phase I trials.
Lee BL; Fan SK; Lu Y
J Biopharm Stat; 2017; 27(1):34-43. PubMed ID: 26882373
[TBL] [Abstract][Full Text] [Related]
5. Designing and evaluating dose-escalation studies made easy: The MoDEsT web app.
Pallmann P; Wan F; Mander AP; Wheeler GM; Yap C; Clive S; Hampson LV; Jaki T
Clin Trials; 2020 Apr; 17(2):147-156. PubMed ID: 31856600
[TBL] [Abstract][Full Text] [Related]
6. Small-sample behavior of novel phase I cancer trial designs.
Oron AP; Hoff PD
Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304
[TBL] [Abstract][Full Text] [Related]
7. A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2.
Guo W; Wang SJ; Yang S; Lynn H; Ji Y
Contemp Clin Trials; 2017 Jul; 58():23-33. PubMed ID: 28458054
[TBL] [Abstract][Full Text] [Related]
8. Bayesian optimization design for dose-finding based on toxicity and efficacy outcomes in phase I/II clinical trials.
Takahashi A; Suzuki T
Pharm Stat; 2021 May; 20(3):422-439. PubMed ID: 33258282
[TBL] [Abstract][Full Text] [Related]
9. Practical model-based dose-finding in phase I clinical trials: methods based on toxicity.
Thall PF; Lee SJ
Int J Gynecol Cancer; 2003; 13(3):251-61. PubMed ID: 12801254
[TBL] [Abstract][Full Text] [Related]
10. Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship.
Guo B; Li Y
BMC Med Res Methodol; 2014 Jul; 14():95. PubMed ID: 25074481
[TBL] [Abstract][Full Text] [Related]
11. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
Xie F; Ji Y; Tremmel L
Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
[TBL] [Abstract][Full Text] [Related]
12. Sample size formulae for the Bayesian continual reassessment method.
Cheung YK
Clin Trials; 2013; 10(6):852-61. PubMed ID: 23965547
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Deviation From Planned Cohort Size and Operating Characteristics of Phase 1 Trials.
Park M; Liu S; Yap TA; Yuan Y
JAMA Netw Open; 2021 Feb; 4(2):e2037563. PubMed ID: 33595664
[TBL] [Abstract][Full Text] [Related]
14. Some thoughts on sample size: a Bayesian-frequentist hybrid approach.
Gordon Lan KK; Wittes JT
Clin Trials; 2012 Oct; 9(5):561-9. PubMed ID: 22865839
[TBL] [Abstract][Full Text] [Related]
15. Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials.
Ji Y; Wang SJ
J Clin Oncol; 2013 May; 31(14):1785-91. PubMed ID: 23569307
[TBL] [Abstract][Full Text] [Related]
16. Bayesian dose-finding phase I trial design incorporating historical data from a preceding trial.
Takeda K; Morita S
Pharm Stat; 2018 Jul; 17(4):372-382. PubMed ID: 29372582
[TBL] [Abstract][Full Text] [Related]
17. A two-stage Bayesian adaptive design for minimum effective dose (MinED)-based dosing-finding trials.
Mu R; Xu G; Liu G; Pan H
Contemp Clin Trials; 2021 Sep; 108():106504. PubMed ID: 34303862
[TBL] [Abstract][Full Text] [Related]
18. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies.
Zhou Y; Lee JJ; Yuan Y
Stat Med; 2019 Dec; 38(28):5299-5316. PubMed ID: 31621952
[TBL] [Abstract][Full Text] [Related]
19. A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.
Zhang L; Yuan Y
Stat Med; 2016 Nov; 35(27):4924-4936. PubMed ID: 27580928
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS).
Pan H; Xie F; Liu P; Xia J; Ji Y
Clin Trials; 2014 Feb; 11(1):49-59. PubMed ID: 24137041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
